SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 726.41+4.9%Dec 10 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (2220)12/8/2017 10:48:41 PM
From: Biotech Jim  Read Replies (2) of 3559
 
The below was from a Jefferies note today:

REGN (Covered by Amin): Dupixent TRx is 3,651 (+39% wk/wk) and NRx is 1,525 (+31% wk/wk)

· TRxes are tracking to 42,931 for Q4 and assuming a weekly growth of 4% based on a 4-wk rolling average for remaining Q4, we would arrive at Dupixent sales of $134.3M for Q4, tracking slightly below consensus of $136.9M.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News